Please wait
Healthcare · Drug Manufacturers - General · Price, fundamentals, signals, and forward-looking context in one research view.
Healthcare
₦195T
3.9%
14.01
Current price
₦95,415.00
0.0% todayUpdated 21 min ago
Open
₦96,840.00
Previous close
₦95,415.00
Day range
₦95,310.00 – ₦97,530.00
Volume
N/A
14.0x P/E
Awaiting filing
3.9% yield
65/100 measured
Moderate liquidity
Recent price movement, key market context and the latest company information.
The latest saved price history for BMY, with its range and direction at a glance.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Investors usually follow BMY for its dividend profile, valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Whisone is bullish because fundamentals are solid at 73/100 while there is no strong bear warning from the current data. Whisone has moderate conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
Latest net profit
₦10.9T
TTM (2026-07-06)
ROE
46.6%
Return on equity
ROA
10.7%
Return on assets
Debt / equity
2.31
Lower is usually safer.
P/B ratio
5.82
Useful for book value support.
Dividend yield
3.9%
Current income signal.
85/100
Direction
Range-bound
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Trading liquidity looks supportive for the forecast to transmit into price action.
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Execution risk and market swings can still delay the forecast playing out.
Fair value
₦97,365.00
Analyst view
Buy
Analyst target
₦99,312.50
Forecast refresh
Updated 20 min ago
Quality score
72
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
₦930.00
2025-01-03
Payment: TBA | Qualification: 2025-01-03 | Yield at declaration: N/A
₦900.00
2024-10-04
Payment: TBA | Qualification: 2024-10-04 | Yield at declaration: N/A
A plain-English reading of momentum, trend, volatility, range position, and trading participation.
RSI
N/A
Momentum data is not available yet.
Recent trend
Rising
+11.7% across the latest saved price window.
Volatility
Low
Beta is 0.23. Price has historically moved more calmly than the wider market.
52-week position
82% of range
Price is trading close to its 52-week high.
Volume confirmation
N/A
Comparable volume data is not available.
q1_2026_gdp_growth
BMY may also move because the HEALTHCARE sector may move with q1_2026_gdp_growth. Confidence 63%.
NBS data cited in the article shows the healthcare sector grew by 1.99% in Q1 2026 (vs 1.76% in Q1 2025), indicating sector-level growth dynamics affecting listed healthcare firms.
local manufacturing / import substitution
BMY may also move because the HEALTHCARE sector may benefit from local manufacturing / import substitution. Confidence 56%.
The article notes Nigeria's pharmaceutical firms are investing in local manufacturing and import substitution to reduce dependence on foreign supply, a trend that supports domestic pharma firms' growth and access.
local_manufacturing_and_access
BMY may also move because the HEALTHCARE sector may benefit from local_manufacturing_and_access. Confidence 56%.
MeCure's emphasis on affordable, locally manufactured medicines and wider market penetration illustrates sector-level support for improved local manufacturing and access to quality medicines.
manufacturing infrastructure
BMY may also move because the HEALTHCARE sector may benefit from manufacturing infrastructure. Confidence 56%.
Completion of a pharmaceutical manufacturing facility by Neimeth increases manufacturing capacity in the healthcare sector.
local_manufacturing_and_product_innovation
BMY may also move because the HEALTHCARE sector may move with local_manufacturing_and_product_innovation. Confidence 53%.
MeCure's focus on deepening local manufacturing, product innovation, and expanded market penetration reflects sector-wide themes of local production and access to affordable medicines.
profit-taking
BMY may also move because the HEALTHCARE sector may move with profit-taking. Confidence 53%.
Profit-taking is identified in the article as a trigger for the sell-off impacting SWOOT stocks.
increased manufacturing capacity
BMY may also move because the HEALTHCARE sector may benefit from increased manufacturing capacity. Confidence 53%.
Neimeth's expansion and completion of a pharmaceutical manufacturing facility will increase production capacity within the healthcare sector.
Halal certification adoption
BMY may also move because the HEALTHCARE sector may benefit from halal certification adoption. Confidence 49%.
Halal certification can increase consumer confidence and market access where Halal-compliant products are important, supporting sector trust and accessibility.
BMY
Bristol-Myers Squibb Company
Price: ₦95,415.00
P/E: 14.011013
Yield: 3.9%
ABBV
AbbVie Inc.
Price: ₦375,135.00
P/E: 70.44788
Yield: 2.8%
ABT
Abbott Laboratories
Price: ₦164,580.00
P/E: 35.62338
Yield: 2.3%
ALGN
Align Technology, Inc.
Price: ₦259,432.50
P/E: 30.026909
Yield: 0.0%
Industry
Drug Manufacturers - General
Employees
32500
Exchange
NYQ
Ticker
BMY
